1,000 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by nVerses Capital LLC

nVerses Capital LLC bought a new position in Biohaven Ltd. (NYSE:BHVN) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,000 shares of the company’s stock, valued at approximately $50,000.

A number of other hedge funds also recently added to or reduced their stakes in BHVN. Redwood Wealth Management Group LLC bought a new stake in Biohaven in the 2nd quarter valued at about $61,000. Elkhorn Partners Limited Partnership bought a new stake in shares of Biohaven during the second quarter valued at approximately $125,000. Quarry LP boosted its position in shares of Biohaven by 614.3% during the second quarter. Quarry LP now owns 5,000 shares of the company’s stock worth $174,000 after buying an additional 4,300 shares during the period. Cypress Wealth Services LLC bought a new position in Biohaven in the 3rd quarter worth approximately $224,000. Finally, Diversified Trust Co acquired a new stake in Biohaven in the 3rd quarter valued at approximately $239,000. 88.78% of the stock is currently owned by institutional investors.

Insider Activity

In other Biohaven news, Director Gregory Bailey acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, September 24th. The stock was purchased at an average cost of $44.19 per share, for a total transaction of $220,950.00. Following the transaction, the director now owns 1,620,071 shares of the company’s stock, valued at $71,590,937.49. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Gregory Bailey bought 5,000 shares of the business’s stock in a transaction on Tuesday, September 24th. The stock was bought at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the transaction, the director now directly owns 1,620,071 shares in the company, valued at $71,590,937.49. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John W. Childs purchased 21,052 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the acquisition, the director now owns 21,052 shares in the company, valued at $999,970. The disclosure for this purchase can be found here. 16.00% of the stock is currently owned by corporate insiders.

Biohaven Trading Down 3.1 %

BHVN stock opened at $51.34 on Tuesday. Biohaven Ltd. has a one year low of $25.97 and a one year high of $62.21. The firm has a 50-day moving average of $43.77 and a two-hundred day moving average of $40.01. The firm has a market capitalization of $4.53 billion, a PE ratio of -7.52 and a beta of 1.31.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($3.64) EPS for the quarter, missing the consensus estimate of ($1.72) by ($1.92). On average, equities research analysts anticipate that Biohaven Ltd. will post -8.82 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on BHVN shares. Bank of America raised their price target on Biohaven from $52.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. UBS Group dropped their price target on shares of Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Royal Bank of Canada increased their price objective on shares of Biohaven from $59.00 to $68.00 and gave the company an “outperform” rating in a report on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and set a $59.00 price objective on shares of Biohaven in a research note on Tuesday, September 24th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a research report on Friday, October 4th. Thirteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $61.92.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.